Literature DB >> 30194188

Serum Carcinoembryonic Antigen Levels Before the First Curative Hepatectomy for Metastatic Colorectal Cancer Is a Predictor of Recurrence.

Hidejiro Kawahara1, Seiya Yoshida2, Yoichi Tohyama2, Satoru Yanagisawa2, Takeyuki Misawa2, Katsuhiko Yanaga3.   

Abstract

BACKGROUND/AIM: The aim of this study was to evaluate the usefulness of serum carcinoembryonic antigen (CEA) levels before the first curative hepatectomy for metastatic colorectal cancer as a predictor of recurrence. PATIENTS AND METHODS: Between 2003 and 2010, 66 patients (45 male and 21 female) who underwent a first curative hepatectomy for metastatic colorectal cancer in our hospital were evaluated retrospectively. The mean patient age was 65.2 years (range=31-80 years). A total of 28 patients had synchronous liver metastasis, and the other 38 patients developed metachronous liver metastasis.
RESULTS: The 5-year relapse-free survival rate after the first hepatectomy of the 16 patients with normal serum CEA level was 61.1%, whereas that of the 50 patients with abnormal serum CEA level was 34.3% (p<0.001). Among patients whose serum CEA levels were abnormal, the 5-year relapse-free survival rate after the first hepatectomy of the 34 patients with serum CEA levels less than 50 ng/ml was 48.1%, whereas that of the 16 patients with serum CEA level equal to or greater than 50 ng/ml was 6.3% (p<0.001). All eleven patients whose serum CEA levels were at least 100 ng/ml developed recurrence within one year after hepatectomy.
CONCLUSION: Serum CEA levels before the first curative hepatectomy for metastatic colorectal cancer seem to be a predictor of recurrence. Copyright
© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Carcinoembryonic antigen; hepatectomy; metastatic colorectal cancer

Mesh:

Substances:

Year:  2018        PMID: 30194188     DOI: 10.21873/anticanres.12863

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  3 in total

1.  Serum CEA and CYFRA Levels in ALK-rearranged NSCLC Patients: Correlation With Distant Metastasis.

Authors:  Takeshi Numata; Takeo Endo; Hidetoshi Yanai; Kyoko Ota; Yusuke Yamamoto; Kei Shimizu; Hideyasu Yamada; Kenji Hayashihara; Shinichiro Okauchi; Hiroaki Satoh; Yutaka Yamada; Tomohiro Tamura; Kazuto Saito; Norihiro Kikuchi; Koichi Kurishima; Hiroichi Ishikawa; Hiroko Watanabe; Toshihiro Shiozawa; Nobuyuki Hizawa; Yasunori Funayama; Shigen Hayashi; Hiroyuki Nakamura; Takaaki Yamashita
Journal:  In Vivo       Date:  2020 Jul-Aug       Impact factor: 2.155

2.  A transcriptomic signature that predicts cancer recurrence after hepatectomy in patients with colorectal liver metastases.

Authors:  Yuma Wada; Mitsuo Shimada; Yuji Morine; Tetsuya Ikemoto; Yu Saito; Hideo Baba; Masaki Mori; Ajay Goel
Journal:  Eur J Cancer       Date:  2022-01-14       Impact factor: 9.162

3.  Programmed death-ligand 1 expression in the tumour stroma of colorectal liver oligometastases and its association with prognosis after liver resection.

Authors:  Jian-Hong Peng; Yi Tai; Yi-Xin Zhao; Bao-Jia Luo; Qing-Jian Ou; Zhi-Zhong Pan; Lin Zhang; Zhen-Hai Lu
Journal:  Gastroenterol Rep (Oxf)       Date:  2020-12-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.